ビラゾドン

ビラゾドン 化学特性,用途語,生産方法

• 効能

  抗うつ薬, セロトニン受容体拮抗・再取り込み阻害薬

• 説明

  In January 2011, the U.S. FDA approved vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a novel antidepressant agent that combines potent serotonin reuptake inhibition (IC₅₀=0.2 nM) with high affinity for 5-HT1A receptors (IC₅₀=0.5 nM)and partial 5-HT1A receptor agonist functional activity. Vilazodone has good selectivity over other monoamine receptors and is efficacious in preclinical models of depression in rats and mice. Vilazodone is an indolylbutylpiperazine derivative that has been prepared by coupling of an indolylbutyl chloride or tosylate with 5-(piperazin-1-yl)benzofuran-2- carboxamide or the corresponding ester. The cyanoindole portion of vilazodone is important for conferring high affinity for both the serotonin transporter and the 5-HT1A receptor. Para-substitution on the phenyl group attached to the piperidine moiety reduces affinity for dopamine receptors, while the carboxamide group provides improved pharmacokinetic properties.

• 化学的特性

  Light Yellow Solid

• 使用

  Labelled analogue of Vilazodone

• 定義

  ChEBI: A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder.

• 作用機序

  The mechanism of action of Vilazodone antidepressant is to enhance the release of serotonin from the serotonergic pathway in the brain by inhibiting the serotonin transporter (similar to a selective serotonin reuptake inhibitor (SSRI)) while stimulating the serotonin-1a receptor through partial agonism. Its agonistic effects are similar to those of the anxiolytic drug buspirone.

• 副作用

  The most common side effects of Vilazodone administered orally include: diarrhoea, dizziness, headache, dry mouth, nausea, vomiting, and sleep disturbances. These symptoms are mild and may disappear within a few days or weeks. Other serious side effects that may occur include: bleeding, hyponatraemia (low levels of sodium in the blood, manifested by dizziness, light-headedness, difficulty concentrating and fainting), mania, seizures (loss of consciousness, twitching of limbs), closed-angle glaucoma (sudden eye pain or loss of vision) and allergic reactions. Seek medical attention if any of these serious adverse symptoms occur.

ビラゾドン 生産企業

Global(242)Suppliers

ビラゾドン スペクトルデータ(¹HNMR)

163521-12-8, ビラゾドン キーワード